Sympathetic tone plays an important role in the control of blood pressure (BP), 1 and a growing body of evidence has implicated abnormal modulation of the sympathetic nervous system (SNS) in the development of hypertension in humans 2 and animals. 3 SNS activity was augmented in salt-loaded spontaneously hypertensive rats and Dahl salt-sensitive rats, 3-5 and α 1 -adrenergic blockade with prazosin produced a marked BP decrease in nitric oxide-deficient hypertensive rats. 6 It was first reported in 2000 that oxidative stress and arterial hypertension were produced in normal Sprague-Dawley rats by oral administration of buthionine sulfoximine (BSO), which induces glutathione (GSH) depletion by selective inhibition of γ-glutamylcysteine synthetase, an enzyme of the GSH biosynthetic pathway. 7 It has been reported that reactive oxygen species stimulate the central and peripheral SNS. 8, 9 Central neural reactive oxygen species play an important role in cardiovascular function, and altered regulation of central redox mechanisms may be implicated in heart failure and hypertension, which are characterized by activation of the SNS. 10,11 Among the target organs of hypertension, the brain is the most affected by oxidative stress, 12,13 and there is evidence that oxidative stress in the brainstem has a pivotal role in the pathogenesis of neural mechanisms in hypertension. 14 The rostral ventrolateral medulla is the vasomotor center that determines basal sympathetic nerve activity. 15 Reactive oxygen species are increased in rostral ventrolateral medulla of strokeprone spontaneously hypertensive rats and contribute to the neural mechanisms of this type of hypertension. 16 Several authors reported that the hypotensive effect of tempol, a membrane-permeable superoxide dismutase mimetic, is accompanied by a reduction in sympathetic nerve activity. 11, [17] [18] [19] [20] In addition, the intracerebroventricular infusion in rabbits of diethyldithiocarbamic acid, a superoxide dismutase inhibitor, significantly increased renal sympathetic nerve activity, 21 and the systemic administration of diethyldithiocarbamic acid in rats increased mean arterial pressure (MAP), heart rate (HR), and renal sympathetic nerve 
Sympathetic tone plays an important role in the control of blood pressure (BP), 1 and a growing body of evidence has implicated abnormal modulation of the sympathetic nervous system (SNS) in the development of hypertension in humans 2 and animals. 3 SNS activity was augmented in salt-loaded spontaneously hypertensive rats and Dahl salt-sensitive rats, [3] [4] [5] and α 1 -adrenergic blockade with prazosin produced a marked BP decrease in nitric oxide-deficient hypertensive rats. 6 It was first reported in 2000 that oxidative stress and arterial hypertension were produced in normal Sprague-Dawley rats by oral administration of buthionine sulfoximine (BSO), which induces glutathione (GSH) depletion by selective inhibition of γ-glutamylcysteine synthetase, an enzyme of the GSH biosynthetic pathway. 7 It has been reported that reactive oxygen species stimulate the central and peripheral SNS. 8, 9 Central neural reactive oxygen species play an important role in cardiovascular function, and altered regulation of central redox mechanisms may be implicated in heart failure and hypertension, which are characterized by activation of the SNS. 10, 11 Among the target organs of hypertension, the brain is the most affected by oxidative stress, 12, 13 and there is evidence that oxidative stress in the brainstem has a pivotal role in the pathogenesis of neural mechanisms in hypertension. 14 The rostral ventrolateral medulla is the vasomotor center that determines basal sympathetic nerve activity. 15 Reactive oxygen species are increased in rostral ventrolateral medulla of strokeprone spontaneously hypertensive rats and contribute to the neural mechanisms of this type of hypertension. 16 Several authors reported that the hypotensive effect of tempol, a membrane-permeable superoxide dismutase mimetic, is accompanied by a reduction in sympathetic nerve activity. 11, [17] [18] [19] [20] In addition, the intracerebroventricular infusion in rabbits of diethyldithiocarbamic acid, a superoxide dismutase inhibitor, significantly increased renal sympathetic nerve activity, 21 and the systemic administration of diethyldithiocarbamic acid in rats increased mean arterial pressure (MAP), heart rate (HR), and renal sympathetic nerve original contributions Sympathetic Tone in BSO-Induced Hypertension activity. 18 Moreover, local administration of tempol or diethyldithiocarbamic acid onto renal sympathetic nerves resulted in dose-dependent decreases or increases in integrated renal sympathetic nerve activity, respectively. 19 The above findings support the notion that oxidative stress regulates sympathetic tone, but its contribution to the pathogenesis of oxidative stress-induced hypertension has not been evaluated. Therefore, the objective of this study was to investigate the role of sympathetic tone in BSO-induced hypertension in mice, evaluating the effects on these animals of chronic α 1 -adrenergic blockade with prazosin and acute ganglionic blockade with pentolinium.
METhOdS
Animals. We used 92 male CBA-C57 mice born and raised at the Granada University animal center. Animal care and work protocols were approved and carried out following the regulations set forth by the Committee of Animal Research and Bioethics of Granada University in accordance with European Union guidelines for the ethical care of animals. Mice initially weighing 20-25 g were randomly assigned to different experimental groups. All animals had free access to standard mice diet with sodium content of 0.5% (rodent toxicology diet; B&K, Barcelona, Spain) and tap water or their respective drinking fluid ad libitum. Each experimental group comprised eight animals, except where stated.
Experimental protocols. Experiment I determined the effects of the chronic administration of increasing doses of BSO to normotensive mice. Mice were assigned to a control group or group given BSO via drinking water at 5 (BSO-5), 10 (BSO-10), or 20 (BSO-20) mmol/l. Treatments were administered for 5 weeks. Body weight (BW), tail systolic BP (SBP), and HR were measured weekly. Tail SBP and HR were measured by tail-cuff plethysmography in un-anesthetized mice (LE 5001-Pressure Meter; Letica, Barcelona, Spain) adapted to the procedure for 1 week. At least seven determinations were made at every session, and the mean of the lowest three values within a range of 5 mm Hg was used to obtain the SBP level.
When the experimental period was completed, all animals were housed in metabolic cages (Panlab, Barcelona, Spain) with free access to food and or their respective drinking fluid for 4 days (2 days for adaptation + 2 experimental days) in order to measure food and fluid intake and collect urine samples. We measured 24-h urine volume, proteinuria, creatinine, and total excretion of sodium, potassium, and isoprostanes. Mean values of the intake and urinary variables obtained during the 2 experimental days were used for statistical analyses.
After completion of the metabolic study, the mice were anesthetized with Equithesin (25 μl/10 g). A polyethylene catheter (PE-50) was inserted into the carotid artery for BP and HR measurements in conscious mice and for extraction of blood samples. Intra-arterial BP was measured at 24 h after implantation of the catheter. Direct BP and HR were recorded continuously for 60 min (MacLab; AD Instruments, Hastings, UK), using the average of the last 30 min to obtain the BP and HR values for intergroup comparisons. Subsequently, blood samples were drawn via the catheter to measure electrolytes, urea, creatinine, noradrenaline, and thyroid hormones. Finally, the mice were killed by complete exsanguination, and the heart and kidneys were weighed. The heart was divided into right ventricle and left ventricle plus septum. Samples from the liver were immediately cleaned, snap-frozen in liquid nitrogen, and stored at −80 °C until their processing for the measurement of total GSH content.
Experiment II determined the effects of chronic α 1 -adrenergic blockade on BP, renal function, and other variables in oxidative stress-induced hypertension. Four groups were used: control, prazosin, 10 mmol/l BSO-treated (BSO-10), and BSO plus prazosin. Prazosin was given via drinking water at a concentration of 10 mg/100 ml. This dose was previously used in a similar protocol in rats 6 and prevents the BP increase produced by a bolus dose of intravenous phenylephrine (10 −6 g) in mice. All treatments were started at the same time and maintained for 5 weeks. The experimental protocol was the same as for experiment I.
Experiment III evaluated the contribution of sympathetic activity to arterial BP and HR in BSO-induced hypertension. Acute BP and HR responses to intravenous injection of pentolinium (10 mg/kg; Sigma, St Louis, MO) were analyzed in conscious controls and BSO-treated mice. After 5 weeks of treatment, the carotid artery and jugular vein were catheterized following a 24-h recovery period. The pentolinium dose was selected because it produces maximal sympathetic inhibition 22 and was previously used in our laboratory to demonstrate differences in sympathetic tone. 23 Decreases in BP and HR are expressed as percentage of the maximal pentolinium-induced inhibition to minimize the effect of differences in the initial value.
Analytical procedures. Plasma and urinary electrolytes and creatinine were measured in an autoanalyzer (Beckman CX4, Fullerton, CA). Urine protein concentration was measured by the method of Bradford. For total F 2 -isoprostane (8-isoprostaglandin F 2α ) determination, urine samples were hydrolyzed by incubation at 40 °C for 90 min with 10 mol/l NaOH. Samples were allowed to cool and then neutralized with 2 mol/l HCl. After centrifugation, the supernatant was collected for assay. Total F 2 -isoprostanes were measured by a competitive enzyme immunoassay (R&D Systems, Minneapolis, MN). Total GSH content of the hepatic tissue was determined with Cayman's GSH assay kit (Cayman Chemical, Ann Arbor, MI). We used enzyme-linked immunosorbent assay kits (IBL International, Hamburg, Germany) to measure plasma noradrenaline concentrations. Plasma thyroid hormone levels were measured with the "ECLIA" electrochemiluminescence immunoassay (Roche Diagnostic, Mannheim, Germany).
Preparation of brainstem homogenates and F 2 -isoprostane measurement.
Brains from control and BSO-10 treated mice (n = 6, each) were rapidly dissected out, snap-frozen in liquid N 2 and stored at −80 °C. Tissue samples were extracted as previously described. 24 Briefly, the brainstem was weighed and original contributions Sympathetic Tone in BSO-Induced Hypertension homogenized (50 mg of tissue/0.5 ml) in 50 mmol/l Tris buffer (pH 7.5) containing 10 µg/ml indomethacin and 10 µmol/l butylated hydroxytoluene to block cyclooxygenase activity and spontaneous oxidation, respectively. Homogenates were centrifuged at 14,000 r.p.m. for 45 min. Supernatants were collected, and undiluted samples were tested for F 2 -isoprostane content. Total F 2 -isoprostanes were measured as reported above.
Histopathological study. For conventional morphology, buffered 4% formaldehyde-fixed, paraffin-embedded longitudinal mouse kidney sections in sagittal plane were stained with hematoxylin and eosin and periodic acid-Schiff stain. The extent of vascular injury (stenosis, hyaline arteriopathy, and myointimal hyperplasia) was assessed by examining profiles of arteries and arterioles in a single kidney section and counting affected vessels. The presence of glomerular lesions (glomerulosclerosis and capsular fibrosis) was assessed in ≥200 glomeruli. Tubular atrophy, necrosis, and tubular casts were also evaluated. The morphological study was done in blinded fashion on 4-µm sections with light microscopy, using the most appropriate stain for each lesion.
Statistical analysis. The behavior of SBP and HR over time was compared by using a nested design, with groups and days as fixed factors and rat as random factor. When the overall difference was significant, Bonferroni's method with an appropriate error was used. One-way analysis of variance was used for comparisons of each variable at the end of experiments. When the overall analysis of variance was significant, we performed pairwise comparisons using Bonferroni's method. P < 0.05 was considered significant. Acute responses to pentolinium were analyzed with unpaired Student's t-test. Results are expressed as means ± s.e.m.
RESulTS

BP and hR
BSO administration produced a dose-related increase in tail SBP and HR in comparison to controls (Figure 1) . Final MAP and HR values measured by direct recording confirmed increased MAP and HR in the BSO groups (Figure 2) , and pulse pressure was also higher in the BSO groups.
Prazosin administration to BSO-10 mice reduced final MAP, HR, and PP values, which were similar between BSO-10+prazosin hepatic gSh content in BSO-treated group BSO-treated animals exhibited a dose-related decrease in total GSH content of liver tissue: control: 5 ± 0.2; BSO-5: 3.1 ± 0.3*; BSO-10: 2.3 ± 0.2*, and BSO-20: 1.2 ± 0.1** (μmol/l/g wet tissue; *P < 0.05, **P < 0.01 vs. controls). Total GSH content in liver was inversely correlated with the tail SBP (r = −0.80, P ≤ 0.001) and HR (r = −0.80, P < 0.001) values at the end of the experimental period.
Brainstem isoprostane levels in BSO-treated group
Brainstem isoprostane levels were higher in BSO-10-treated mice than in controls (controls: 0.13 ± 0.02; BSO-10: 0.25 ± 0.05 pg/mg tissue, P < 0.01). 
Morphological variables
All BSO-treated groups showed a slight but significant reduction in BW gain vs. controls ( Table 1) . Prazosin treatment did not significantly modify BW gain vs. controls or BSO-treated mice. Kidney-to-BW ratios, left ventricular-to-BW ratios, and left ventricular-to-heart weight ratios were not affected by BSO or prazosin treatments ( Table 1) . No lesions were detected in control or BSO-treated mice, and no tubulointerstitial, glomerular, or vascular lesions were present in renal parenchyma.
Plasma, metabolic, and urinary variables
There were no significant intergroup differences in plasma sodium, potassium, total protein, urea, or creatinine in experiments I or II (data not shown). Plasma noradrenaline concentration was elevated in BSO-treated mice ( Table 2) . Similar plasma levels of free T 4 and free T 3 were found in control and BSO-10 groups (FT 4 (ng/dl): control, 1.76 ± 0.14; BSO-10, 2.00 ± 0.34; FT 3 (pg/ml): control 4.14 ± 0.22; BSO-10, 4.64 ± 0.36). Metabolic studies at the end of treatment showed similar food and fluid intakes (g/30 g BW) in all groups in both experiments ( Table 2 ). Water and sodium balances, proteinuria, and creatinine clearance were also unaffected by BSO or prazosin treatments. Total isoprostane excretion was significantly increased in the BSO-10 group. These data are summarized in Table 2 .
dISCuSSION
The contribution of several potential pathogenic factors has been evaluated in the BSO rat model, the prototype of oxidative stress-induced hypertension. These include vascular reactivity, 25, 26 renin-angiotensin system activity, 27 TXA2-PgH2 
original contributions
Sympathetic Tone in BSO-Induced Hypertension production, 25, 27 renal dopamine-induced natriuresis, 28 and endothelium-derived factors. 7, 29 However, the contribution of the sympathetic tone to this model of hypertension has not been evaluated. Therefore, the goal of this study was to determine the contribution of the SNS to the increased BP and HR of BSO hypertensive mice and to develop a GSH-deficient model of hypertension in mice. We found that BSO-induced hypertension is accompanied by increased brainstem and urinary levels of isoprostanes and increased plasma levels of noradrenaline. We also observed that chronic α 1 -adrenergic blockade with prazosin prevents the hypertension and increased HR of BSOtreated mice, and that acute ganglionic blockade with pentolinium produces greater percentage MAP and HR decreases in BSO-treated mice than in controls. Hence, we propose that BSO increases central and peripheral oxidative stress, which may produce a central or peripheral activation of sympathetic tone that elevates resting BP and HR in BSO-treated mice. Several studies demonstrated that oxidative stress plays a major role in the central and peripheral modulation of sympathetic activity, 8, 9, [17] [18] [19] [20] and oxidative stress was reported to increase the sympathetic tone in various types of experimental hypertension. 11, 16, 17 Moreover, the BP-lowering effect of some antihypertensive drugs has been associated with a reduction in brainstem oxidative stress. [30] [31] [32] Collectively, these observations suggest an important role for oxidative stress-induced sympathetic activation in hypertension.
Our results demonstrate that BSO administration produces a dose-related increase in HR. Only a few studies reported Data expressed as means ± s.e.m. BSO, buthionine sulfoximine; ∆BW, gain in body weight; FBW, final body weight; KW/BW, ratio of kidney weight-to-body weight; LVW/BW, ratio of left ventricular weight-to-body weight; LVW/HW, ratio of left ventricular weight-to-heart weight. *P < 0.05 vs. control group. 25 administered BSO to Sprague-Dawley rats for 24 h and reported that MAP and HR values followed a parallel time course in both variables, although they found no HR modification after BSO treatment for 1 week. 25 In consonance with the present data, an increase in oxidative stress induced by the systemic administration of the superoxide dismutase inhibitor diethyldithiocarbamic acid produced increases in MAP, HR, and renal sympathetic nerve activity, 19 and these variables were reduced after systemic administration of tempol, an antioxidant superoxide dismutase mimetic. [18] [19] [20] These studies also suggest that the dose-response increase in BP and HR in BSOtreated mice may be secondary to an increased sympathetic activity induced by greater oxidative stress. Moreover, species difference in the cardiac response to BSO might participate in the increased HR in BSO-treated mice.
Because the simultaneous rise in BP and HR in BSO-treated mice resembles the hemodynamic manifestations of a hyperthyroid state, 33 we also measured plasma thyroid hormone levels. These were similar between controls and BSO-treated mice, ruling out the possible contribution of an increased thyroid function in oxidative stress-induced hypertension.
The mechanism by which BSO increases sympathetic tone has yet to be fully elucidated, but a possible explanation is an enhanced nitric oxide inactivation induced by increased oxidative stress resulting from reaction with superoxide anion. Thus, nitric oxide negatively modulates the activity of the norepinephrine portion of sympathetic neurotransmission, 34 and BSO-induced hypertension has been associated with a reduced nitric oxide bioavailability produced by reactive oxygen species. 29 We decided to adapt the BSO hypertension model to mice, despite the technical difficulties of handling the diminutive organs and blood vessels, because the use of mice rather than rats reduces the cost of the experiments and permits a longer study period, especially given the high price of BSO. It also permits a better comparison with transgenic and gene knockout mice, the most successfully and widely used species, which have altered antioxidant or pro-oxidant factors. Our results show a decreased hepatic GSH content in BSOtreated mice, in agreement with rat studies, 7, 25, 29 indicating the efficacy of the procedure. We also found augmented brainstem levels and urinary excretion of isoprostanes, considered a sensitive and reliable index of oxidative stress in vivo, 35 in concordance with previous observations. 27, 28 Hence, our data verify the presence of increased oxidative stress in BSO-treated mice.
Serum creatinine concentration, creatinine clearance, and urinary protein excretion values were similar between BSOtreated groups and controls. Furthermore, light microscopy studies found no morphological abnormalities in the kidneys of BSO-treated mice. Similar findings were reported in rats after 2 weeks of BSO administration, 7, 28, 29 suggesting that oxidative stress per se cannot induce discernible renal disease and/ or structural abnormalities of the kidney, at least in the period analyzed in this study.
The relative left ventricular weight was unchanged in our BSO-treated mice, despite their hypertension, in agreement with reports by Ford et al. 26 in rats treated with BSO (20 and 30 mmol/l) for 10 days. Our results are also concordant with the findings of Johns et al., 36 who made the unexpected observation that renovascular and deoxycorticosterone acetate-salt hypertensive mice did not develop cardiomegaly after 4 weeks of hypertension induction, in contrast to the widely reported cardiac hypertrophy of these models in rats. The above findings suggest a reduced sensitivity to develop cardio megaly in mice. Moreover, the absence of cardiac and renal hypertrophy observed in BSO-treated mice may be related to a decreased expression of α-tubulin in renal tissue (unpublished observations), as cytoskeletal proteins are particularly susceptible to oxidative stress. Thus, that α-tubulin was demonstrated to be a major carbonylation target in rat brain after GSH depletion. 37 In conclusion, this study provides evidence that an increased sympathetic tone plays a major role in the elevated BP and HR of BSO-induced hypertension in mice. Our results also indicate that this model of hypertension in mice is not accompanied by cardiac hypertrophy or by functional or morphological signs of renal injury after a period of 5 weeks.
